Evaluation of Serum, Saliva and GCF Visfatin Levels in Chronic Periodontitis Patients with Uncontrolled /Controlled Type2 Diabetes Mellitus

Yıl 2021, Cilt: 8 Sayı: 3, 817 - 823, 31.12.2021

Mustafa Cihan Yavuz , Cenk Fatih Çanakçı

https://doi.org/10.15311/selcukdentj.1009374

Cited By: 1

Öz

Background: Visfatin is a multifaceted protein that plays an important role in diabetes (DM) and periodontitis (CP). It has been known that during inflammation, the production of IL-1b, TNF-a can be induced by visfatin. Therefore, visfatin is an important mediator for both diseases. The aim of this study is to investigation of visfatin levels in serum, saliva and GCF samples of non-diabetic periodontitis patients and controlled and uncontrolled diabetic periodontitis patients, and evaluation of the relationship with clinical and biochemical parameters of periodontitis
Methods: Study protocol, 5 groups which each one were consisted of 15 subjects were planned: periodontally healthy patients with systemically healthy (DM-P-); patients with systemically healthy and CP (DM-P+), periodontally healthy patients with diabetes (DM+P-), patients with diabetes and CP (DM+P+), patients with uncontrolled diabetes and CP (uDM+P). Serum, saliva and GCF samples were obtained and, levels of visfatin, TNF-α and IL-1β were determined by ELISA.
Results: The highest visfatin, TNF-α and IL-1β levels were seen in (uDM+P+) group (p>0.001). Significant positive correlations between GCF visfatin levels and GCF TNF-α and IL-1β levels were detected in (uDM+P+) group (p<0.001).
Conclusions: Elevated visfatin levels of serum, saliva and GCF in patients with DM and CP may be related with both diseases and interaction between DM and CP.

Anahtar Kelimeler

Visfatin, TNF-a, IL1-b, periodontitis, diabetes mellitus

Kaynakça

• 1- Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000). The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes care, 23(8), 1108-1112.
• 2- Löe, H. (1993). Periodontal disease: the sixth complication of diabetes mellitus. Diabetes care, 16(1), 329-334.
• 3- Genco, R. J. (1992). Host responses in periodontal diseases: current concepts. Journal of periodontology, 63, 338-355.
• 4- Graves, D. T., & Cochran, D. (2003). The contribution of interleukin‐1 and tumor necrosis factor to periodontal tissue destruction. Journal of periodontology, 74(3), 391-401.
• 5- Buduneli, N., & Kinane, D. F. (2011). Host‐derived diagnostic markers related to soft tissue destruction and bone degradation in periodontitis. Journal of clinical periodontology, 38, 85-105.
• 6- Pradeep, A. R., Raghavendra, N. M., Prasad, M. R., Kathariya, R., Patel, S. P., & Sharma, A. (2011). Gingival crevicular fluid and serum visfatin concentration: their relationship in periodontal health and disease. Journal of periodontology, 82(9), 1314-1319.
• 7- Azamar-Llamas, D., Hernandez-Molina, G., Ramos-Avalos, B., & Furuzawa-Carballeda, J. (2017). Adipokine contribution to the pathogenesis of osteoarthritis. Mediators of inflammation, 2017.
• 8- Ognjanovic, S., Bao, S., Yamamoto, S. Y., Garibay-Tupas, J., Samal, B., & Bryant-Greenwood, G. D. (2001). Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. Journal of molecular endocrinology, 26(2), 107-118.
• 9- Moschen, A. R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H., & Tilg, H. (2007). Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. The Journal of Immunology, 178(3), 1748-1758.
• 10- Hammarstedt, A., Pihlajamäki, J., Rotter Sopasakis, V., Gogg, S., Jansson, P. A., Laakso, M., & Smith, U. (2006). Visfatin is an adipokine, but it is not regulated by thiazolidinediones. The Journal of Clinical Endocrinology & Metabolism, 91(3), 1181-1184.
• 11- Heo, Y. J., Choi, S. E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., ... & Kim, H. J. (2019). Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes. Journal of diabetes research, 2019.
• 12- Stastny, J., Bienertova-Vasku, J., & Vasku, A. (2012). Visfatin and its role in obesity development. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 6(2), 120-124.
• 13- Nourbakhsh, M., Nourbakhsh, M., Gholinejad, Z., & Razzaghy-Azar, M. (2015). Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. Scandinavian Journal of Clinical and Laboratory Investigation, 75(2), 183-188.
• 14- Heo, Y. J., Choi, S. E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., ... & Kim, H. J. (2019). Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes. Journal of diabetes research, 2019.
• 15- Pradeep, A. R., Raghavendra, N. M., Sharma, A., Patel, S. P., Raju, A., Kathariya, R., ... & Naik, S. B. (2012). Association of serum and crevicular visfatin levels in periodontal health and disease with type 2 diabetes mellitus. Journal of periodontology, 83(5), 629-634.
• 16- Mopidevi, A., Penmetsa, G. S., Dwarkanath, C. D., Dubba, K., & Gadde, P. (2019). Salivary visfatin concentrations in patients with chronic periodontitis: An analysis before and after periodontal therapy. Indian Journal of Dental Research, 30(6), 864.
• 17- Bahammam, M. A., & Attia, M. S. (2018). Effects of systemic simvastatin on the concentrations of visfatin, tumor necrosis factor-α, and interleukin-6 in gingival crevicular fluid in patients with type 2 diabetes and chronic periodontitis. Journal of immunology research, 2018.
• 18- Tabari, Z. A., Keshani, F., Sharbatdaran, M., Banishahabadi, A., Nejatifard, M., & Ghorbani, H. (2018). Visfatin expression in gingival tissues of chronic periodontitis and aggressive periodontitis patients: An immunohistochemical analysis. Dental research journal, 15(2), 104.
• 19- McGlothlin, J. R., Gao, L., Lavoie, T., Simon, B. A., Easley, R. B., Ma, S. F., ... & Ye, S. Q. (2005). Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochemical genetics, 43(3-4), 127-141.
• 20- Sandeep, S., Velmurugan, K., Deepa, R., & Mohan, V. (2007). Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism, 56(4), 565-570.
• 21- Nishimura, F., Iwamoto, Y., Mineshiba, J., Shimizu, A., Soga, Y., & Murayama, Y. (2003). Periodontal disease and diabetes mellitus: the role of tumor necrosis factor‐α in a 2‐way relationship. Journal of periodontology, 74(1), 97-102.
• 22- Graves, D. T., & Cochran, D. (2003). The contribution of interleukin‐1 and tumor necrosis factor to periodontal tissue destruction. Journal of periodontology, 74(3), 391-401.
• 23- Paraskevas, S., Huizinga, J. D., & Loos, B. G. (2008). A systematic review and meta‐analyses on C‐reactive protein in relation to periodontitis. Journal of clinical periodontology, 35(4), 277-290.